FDA Accepts Arcutis sNDA for ZORYVE Cream in Infants with Atopic Dermatitis

Key Facts

In a move reflecting the expanding reach of specialized dermatology biotech firms, Arcutis Biotherapeutics announced that the FDA has accepted its supplemental New Drug Application (sNDA) for ZORYVE cream 0.05%. The application seeks to expand the treatment's indication to include infants aged 3 to 24 months suffering from atopic dermatitis. The regulatory agency has established a PDUFA target action date of February 23, 2027, to conclude its review.

The submission is backed by positive data from the Phase 2 INTEGUMENT-INFANT trial, targeting a significant unmet need for approximately 1 million children under age two in the U.S. Arcutis is positioned to compete in the non-steroidal topical market against established players like Pfizer, which markets Eucrisa. Per market data, expanding the label to younger pediatric populations is a critical driver for the long-term commercial trajectory of the roflumilast franchise.

Regarding market performance, ARQT shares stood at $27.67 at the close of July 07, 2026, after hitting a session high of $27.8. Investors should note that while the FDA acceptance is a positive milestone, the final decision catalyst is scheduled for early 2027. In the absence of immediate sector-specific catalysts in the upcoming economic calendar, market attention will likely remain on quarterly execution and prescription growth trends for the existing ZORYVE labels.